inclusion criteria: 1. adults of either gender aged ≥18 years. 2. participant has not had covid-19 in the previous 6 months. 3. the participant has not been vaccinated against covid-19 or other viral infections in the previous 6 months. 4. negative rapid test result for sars-cov-2 (covid-19 ag). 5. absence of clinical manifestations of any infectious disease, but not earlier than 14 days from its onset. 6. consent to use reliable contraceptive methods during the study (for men and women with reproductive potential). 7. presence of a signed information sheet and informed consent form for participation in a clinical trial.

inclusion criteria: 1. adults of either gender aged ≥18 years. 2. participant has not had covid-19 in the previous 6 months. 3. the participant has not been vaccinated against covid-19 or other viral infections in the previous 6 months. 4. negative rapid test result for sars-cov-2 (covid-19 ag). 5. absence of clinical manifestations of any infectious disease, but not earlier than 14 days from its onset. 6. consent to use reliable contraceptive methods during the study (for men and women with reproductive potential). 7. presence of a signed information sheet and informed consent form for participation in a clinical trial.

inclusion criteria: adults of either gender aged ≥18 years. participant has not had covid-19 in the previous 6 months. the participant has not been vaccinated against covid-19 or other viral infections in the previous 6 months. negative rapid test result for sars-cov-2 (covid-19 ag). absence of clinical manifestations of any infectious disease, but not earlier than 14 days from its onset. consent to use reliable contraceptive methods during the study (for men and women with reproductive potential). presence of a signed information sheet and informed consent form for participation in a clinical trial.

inclusion criteria: adults of either gender aged ≥18 years. participant has not had covid-19 in the previous 6 months. the participant has not been vaccinated against covid-19 or other viral infections in the previous 6 months. negative rapid test result for sars-cov-2 (covid-19 ag). absence of clinical manifestations of any infectious disease, but not earlier than 14 days from its onset. consent to use reliable contraceptive methods during the study (for men and women with reproductive potential). presence of a signed information sheet and informed consent form for participation in a clinical trial.

inclusion criteria: 1. adults of either gender aged ≥18 years. 2. participant has not had covid-19 in the previous 6 months. 3. the participant has not been vaccinated against covid-19 or other viral infections in the previous 6 months. 4. negative rapid test result for sars-cov-2 (covid-19 ag). 5. absence of clinical manifestations of any infectious disease, but not earlier than 14 days from its onset. 6. consent to use reliable contraceptive methods during the study (for men and women with reproductive potential). 7. presence of a signed information sheet and informed consent form for participation in a clinical trial.

inclusion criteria: 1. adults of either gender aged ≥18 years. 2. participant has not had covid-19 in the previous 6 months. 3. the participant has not been vaccinated against covid-19 or other viral infections in the previous 6 months. 4. negative rapid test result for sars-cov-2 (covid-19 ag). 5. absence of clinical manifestations of any infectious disease, but not earlier than 14 days from its onset. 6. consent to use reliable contraceptive methods during the study (for men and women with reproductive potential). 7. presence of a signed information sheet and informed consent form for participation in a clinical trial.